10-Q: Vicarious Surgical Faces Going Concern Doubt Despite Q3 Loss Reduction

Vicarious Surgical Inc. reported a reduced net loss for Q3 2025, but faces substantial doubt about its ability to continue as a going concern despite a recent $5.2 million capital raise.

Summary

• Net loss for the nine months ended September 30, 2025, was $39.67 million, an improvement from $49.30 million in the prior year period.
• Operating expenses decreased by 21% to $40.77 million for the nine months ended September 30, 2025, primarily due to reduced personnel-related expenses and professional services.
• Cash, cash equivalents, and short-term investments totaled $13.41 million as of September 30, 2025.
• The company completed a registered direct offering and concurrent private placement in October 2025, raising approximately $5.2 million in net proceeds.
• Management believes current capital, even with the recent raise, will not be sufficient to support operations for the next 12 months, raising substantial doubt about the company's ability to continue as a going concern.
• The company is developing the Vicarious Surgical System, a single-port surgical robot, with a clinical-ready version expected by mid-2026 and first-in-human trials anticipated in 2027.
• Material weaknesses in internal control over financial reporting were identified as of December 31, 2024, and disclosure controls were not effective as of September 30, 2025.
• The company received a notice from the NYSE on April 10, 2025, regarding non-compliance with minimum market capitalization and stockholders' equity standards, but its remediation plan was accepted on July 8, 2025, with an 18-month cure period.

Sentiment

Score: 3

Explanation: While the company reduced its net loss and operating expenses, the explicit 'going concern' warning, significant decline in assets and equity, and identified material weaknesses in internal controls indicate a highly precarious financial position. The recent capital raise provides some short-term relief but is insufficient for the next 12 months, highlighting severe funding challenges for a pre-revenue company with long development timelines.

Positives

• Net loss for the nine months ended September 30, 2025, decreased to $39.67 million from $49.30 million in the prior year, representing a 20% improvement.
• Loss from operations improved by 21% for the nine months ended September 30, 2025, primarily due to a $6.74 million decrease in personnel-related expenses and a $4.96 million decrease in professional services.
• Research and development expenses decreased by 17% to $26.46 million for the nine months ended September 30, 2025.
• Sales and marketing expenses decreased by 51% to $1.74 million for the nine months ended September 30, 2025.
• General and administrative expenses decreased by 23% to $12.57 million for the nine months ended September 30, 2025.
• Net cash used in operating activities decreased to $35.76 million for the nine months ended September 30, 2025, from $38.17 million in the prior year.
• Net cash provided by investing activities significantly improved to $29.12 million for the nine months ended September 30, 2025, compared to $7.59 million used in the prior year, largely due to proceeds from sales and maturities of available-for-sale investments.
• The NYSE accepted the company's plan to regain compliance with listing standards, providing an 18-month cure period.
• Completed two controlled builds of the Vicarious Surgical platform in April and August 2025, demonstrating reproducibility and scalability.

Negatives

• The company has an accumulated deficit of $235.60 million and has not yet generated any revenue from operations.
• Management does not believe current cash, cash equivalents, and short-term investments, even with the recent $5.2 million capital raise, will be sufficient to support operations for the next 12 months, raising substantial doubt about the company's ability to continue as a going concern.
• Total current assets significantly decreased to $15.08 million as of September 30, 2025, from $51.70 million as of December 31, 2024.
• Total stockholders' equity significantly decreased to $14.09 million as of September 30, 2025, from $46.70 million as of December 31, 2024.
• Interest and other income decreased by 68% to $868k for the nine months ended September 30, 2025, due to a decrease in interest income from short-term investments.
• Identified material weaknesses in internal control over financial reporting as of December 31, 2024, and disclosure controls were not effective as of September 30, 2025.
• The company's Class A common stock was non-compliant with NYSE's Minimum Market Capitalization Standard as of April 10, 2025.

Risks

• Uncertainties related to the ability to achieve a revenue-generating product.
• Current and potential competitors with greater financial, technological, production, and marketing resources.
• Dependence on key management personnel.
• Ability to raise additional capital, as needed, which may not be available in sufficient amounts or on acceptable terms.
• Inability to maintain the listing of Class A common stock on the New York Stock Exchange (NYSE).
• The success, cost, and timing of product and service development activities.
• The approval, commercialization, and adoption of initial product candidates and future product candidates.
• Ability to obtain and maintain regulatory authorization for the Vicarious Surgical System on the expected timeline, and without unexpected restrictions.
• Changes in U.S. and foreign laws.
• Ability to identify, in-license, or acquire additional technology.
• Ability to maintain existing license agreements and manufacturing arrangements and scale manufacturing to commercial quantities.
• Ability to compete with other companies in ventral hernia repair and additional surgical applications, as well as with open surgeries.
• The size and growth potential of the markets for the Vicarious Surgical System.
• Estimates regarding expenses, future revenue, capital requirements, cash runway, and needs for additional financing.
• The ongoing effect of the reverse stock split on the price or trading of Class A common stock, including potential continued adverse impacts on liquidity.
• Intellectual property rights and the ability to protect or enforce these rights.
• Ability to address economic downturns and political and market conditions beyond control, including increasing expenses, cost of capital, and supply chain impacts.
• If the NYSE delists Class A common stock, it could lead to limited market quotations, reduced liquidity, limited news/analyst coverage, and decreased ability to obtain additional financing.
• The sale of equity and convertible debt securities may result in dilution to stockholders.
• Preferred equity securities or convertible debt could provide for rights, preferences, or privileges senior to those of common stock.
• Terms of debt securities or borrowings could impose significant restrictions on operations.
• Raising funds through collaborations and licensing arrangements might require relinquishing significant rights or granting licenses on unfavorable terms.
• If capital is not available when needed or on attractive terms, the company could be forced to significantly delay, scale back, or discontinue development, market authorization, or commercialization.
• Material weaknesses in internal control over financial reporting could adversely affect the ability to record, process, summarize, and report financial information.

Future Outlook

The company expects to field a clinical-ready version of its Vicarious Surgical System by mid-2026, with design-freeze targeted by the end of 2026. Subject to regulatory clearance, first-in-human clinical trials are anticipated to begin in 2027. However, the company does not expect its current capital, even with recent financing, to be sufficient for the next 12 months, indicating a need for substantial additional funding to complete clinical trials, obtain market authorization, and commercialize its product.

Management Comments

• "We are combining advanced miniaturized robotics, computer science, sensing and 3D visualization to build a new category of intelligent and affordable, single-port surgical robot that virtually transports surgeons inside the patient to perform minimally invasive surgery."
• "With our next-generation robotics technology that is being designed with proprietary human-like motion, we are seeking to improve patient outcomes, as well as the cost and efficacy of surgical procedures."
• "We intend to deliver the next generation in robotic surgery, designed to solve the shortcomings of both open surgery, as well as current manual and robot-assisted minimally invasive surgery."
• "The single-port Vicarious Surgical System with advanced, miniaturized robotics and exceptional visualization is designed to address the significant limitations of open surgery and existing singleand multi-port robotic surgical approaches to improve patient outcomes and enhance adoption by hospitals and other medical facilities."
• "We expect R&D expenses to vary over time depending on the level and timing of our new product development efforts, as well as our clinical development, clinical trial and other related activities."
• "We expect G&A expenses to continue to increase in absolute dollars as we expand our infrastructure to both drive and support the anticipated growth due to additional legal, accounting, insurance and other expenses associated with being a public company."
• "We expect S&M expenses to continue to increase in absolute dollars as we increase potential customers awareness of our presence and prepare our sales and marketing function for our product launch at a future, yet undetermined date."

Industry Context

Vicarious Surgical operates in the highly competitive and capital-intensive medical robotics industry, aiming to disrupt the market for minimally invasive surgery. The company highlights limitations of existing robotic systems, such as high costs (up to $2.0 million upfront plus 10-20% annual maintenance), limited capabilities, and low utilization, which it seeks to overcome with its differentiated single-port system. The slow adoption of current robot-assisted surgery, with over 50% of soft tissue procedures still performed via open surgery, indicates a significant market opportunity for innovative, more accessible solutions. However, the industry is characterized by stringent regulatory hurdles (FDA approval) and requires substantial ongoing R&D investment, which Vicarious Surgical is currently navigating without revenue generation.

Comparison to Industry Standards

• Existing robotic systems are cited as having high upfront acquisition costs of up to $2.0 million or more per system, plus an additional 10% to 20% annually for maintenance and service contracts, which Vicarious Surgical aims to improve upon with its more affordable design.
• Current robot-assisted minimally invasive surgery is used in less than 5% of the estimated 45 million soft tissue surgical procedures annually worldwide, indicating a significant market gap that Vicarious Surgical's technology aims to address by improving accessibility and capabilities.
• The company's system is designed to overcome limitations of existing robotic systems, such as limited degrees of freedom, complicated robotic motion outside the body, difficulty operating in multiple quadrants, and collision issues, which restrict natural surgeon movements and require extensive training.

Corporate Governance

Stakeholder Impact

• Shareholders: Face significant dilution risk from potential future equity raises and the recent offering. The "going concern" warning and NYSE non-compliance pose substantial risks to investment value and liquidity. The reverse stock split in 2024 already adjusted per-share metrics.
• Employees: Headcount reductions (7% overall, 56% in S&M, 25% in G&A) indicate cost-cutting measures, potentially impacting morale and future employment stability. Stock-based compensation remains a component of overall compensation.
• Creditors: The "going concern" warning and need for additional financing increase credit risk.
• Customers (future): The long development timeline (first-in-human trials in 2027) means product availability is still years away, impacting potential future customers.

Next Steps

• Actively pursue additional equity or debt financing to address capital needs.
• Field a clinical-ready version of the Vicarious Surgical System by mid-2026.
• Target design-freeze for the Vicarious Surgical System by the end of 2026.
• Initiate first-in-human clinical trials in 2027, subject to regulatory clearance.
• Continue to invest in commercialization and new product development.
• Continue hiring additional accounting, finance, and legal resources with public company experience to remediate material weaknesses.
• Implement additional review controls and processes for timely account reconciliation and transaction analysis.
• Hold a meeting of stockholders within 120 days of October 9, 2025, to seek approval for the exercise of common warrants.
• The NYSE will review compliance with the listing plan quarterly during the 18-month cure period.

Key Dates

Recommendation

The company explicitly states "substantial doubt about our ability to continue as a going concern" due to insufficient capital for the next 12 months, even after a recent $5.2 million capital raise. This, combined with a significant decline in total current assets and stockholders' equity, identified material weaknesses in internal controls, and ongoing pre-revenue status with a long development timeline (first-in-human trials in 2027), paints a dire financial picture. While operating losses were reduced, the fundamental liquidity and solvency issues are paramount. The NYSE non-compliance further underscores the precarious position. Investors face high risk of significant capital loss and potential delisting.

Keywords

Robotic Surgery, Minimally Invasive Surgery, Ventral Hernia Repair, Surgical Robotics, Medical Devices, FDA Approval, SEC Filing, 10-Q, Financial Results, Going Concern, Capital Raise, NYSE Listing, RBOT, Vicarious Surgical System, Healthcare Technology